Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Press release - No. 13/2017
Zealand Pharma: Invitation to Capital Market Day in New York on 25 January, and event in Copenhagen on 29 January 2018
- Zealand's management will provide an update on strategy and business
- Keynote presentations from two key opinion leaders
Copenhagen, Denmark, December 21, 2017 - Zealand announces that it will host a Capital Market Day for investors and analysts in New York on Thursday 25 January 2018 at 12 to 3 pm, followed by an event in Copenhagen on Monday 29 January 2018, where external speakers will not be present.
The Capital Market Days will include an update on the status of Zealand's business and its progress towards becoming a leader in specialty gastrointestinal and metabolic diseases. Management will present the progress and outlook for glepaglutide for the treatment of short bowel syndrome and dasiglucagon for diabetes care and treatment of congenital hyperinsulinsm (CHI) as well as an update on the strong research pipeline.
In addition, we are proud to present two external speakers:
- David F. Mercer, M.D., Ph.D., associate professor in the UNMC Department of Surgery-Transplant and director of Nebraska Medicine's Intestinal Rehabilitation Program, will provide important insights regarding the treatment of short bowel syndrome.
- Jessica Castle, M.D. will provide a clinician perspective of glucagon. Jessica Castle is as an assistant professor at the Harold Schnitzer Diabetes Health Center, Portland.
| Capital Markets Day in New York Date: | Thursday, 25 January 2018 |
| Time: | 12:30 - 3:00 pm ET (lunch will be served from 12:00 pm) |
| Venue: | Dechert Law Firm offices, 1095 Avenue of the Americas, at the corner of 42th West facing Bryant Park, New York City |
| Registration: | Before end of business Tuesday, 23 January 2018 to Lifesci Advisors on link http://events.constantcontact.com/register/event?llr=mlhnstzab&oeidk=a07eeyd09t8aa34d70d |
| Webcast: | http://lifesci.rampard.com/20180125/. |
| Capital Markets Event in Copenhagen Date: | Monday, 29 January 2018 |
| Time: | 13:30 - 16:00 CET |
| Venue: | Zealand Pharma, Smedeland 36, 2600 Glostrup |
| Webcast: | This event will not be webcasted, but the presentations from the two key opinion leaders from the New York event will be shown. |
| Registration: | Before January 26 2018 by mail [email protected] |
For further information, please contact:
Mats Blom, Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim, and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/6201d801-1afa-4c0f-8e08-ea82cbe9c8a5
